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Clonidine in the Management of 
Uncontrolled Hypertension 
W. F. LUBBE 
SUMMARY 
The antihypertensive effect of clonldine hydrochloride 
(Catapres) was investigated in patients with uncontrolled 
hypertension. In 25 ambulant atQatisnts a double-blind 
crossover Mal was performed by adding donidine or Its 
placebo at random in succession for a month, to existing 
antihypertensive regimens. A second gmup of patients 
with severe h-on and renal failure was investigated 
in a single-blind fashion. In h double-blind study. 21 
patients completed the Mal. Sitting blood pressures were 
ie8=t7,2 i53*4,3 
standing blood pl.buures fmm -to - mmHg 
121A3.2 97k2.7 
(P<QOOl). Them was no inorsrcre In postural effect. 
Placebo treabnent caused only a small decrease In systoljc 
plr~wss, but no dacnrrrw, in disdolic pressures. Forty- 
four per cent of pa!ienb W botherromct reclstion and 
*/b collrplalned of a dry mouth. In the dngbblind study, 
he  mean fdlow-up p e d  for 11 patienu war 14.6 months. 
burh,g this time with clonidine included In their regimens. 
renal function debhmed in 2 pdenb, improved in 5 
and remained unchanged in 4. The drug exerted a power- 
ful antihypertensive effect in the Hlplne position In many 
of these patients. Ctonidlnb b a useful 7
drug, particulruly in pathnts with compromised ml 
functkn. 
S. Afr. Med. 1.. 48, 391 (1974). 
Treatment of patients with mild to moderate hypertension 
with a diuretic and one of a number of modem anti- 
hypertensive drugs causes a dramatic reduction in the mor- 
bidity and mortality associated with hypertensive disease?' 
Such simple treatment regimens are associated with a 
negligible incidence of side-&ects attributable to the drugs, 
since relatively small amounts are used. On the other hand, 
the management of severe and malignant forms of hyper- 
tension often presents a formidable challenge. Unless 
actively and effectively treated, such patients often succumb 
to complications of their disease within a few months. 
Their therapy is often complicated by the fact that 
several drugs have to be w d  in large amounts and the 
sideeffects of the drugs used may not only add significant 
problems, but may adversely affect the prognosis of the 
patient. The search for more satisfactory drugs to we in 
these patients, therefore, has to continue. 
The purpose of this study was to evaluate by double- 
blind trial the use of the new antihypertensive drug, 
clonidine hydrochloride, in patients with moderate to 
severe hypertension, who were either not responding 
satisfactorily to their existing treatment regimens, or in 
whom side-effects of other drugs impaired their effective 
control. A single-blind study was also conducted in a 
separate group of patients with malignant hyperteasion or 
hypertension with significant renal failure, with special 
reference to whether the drug acted effectively whik these 
patients were confined to bed. 
PATIENTS AND METEOW: 
ca*l bLi. d of ~e-dtcim+ G- Sdmm DoubIcBhd Crossover Group 
Hospital aud Udvercnty d Cape Town 
W. F. LUBBE, M.D., F.C.P. (s.A.), C d t o n t  Pkysfcian and TwenW-five a d d a n t  hypefieGve patients attending 
Lecturer the Groote Schuur Hospital Hypertension Clinic were 
 ate received: 2s ~cptankr  19% selected for the reason that their blood pressures were 
9 
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Daily dose of medications
A 1500; D 2
A 1500; D 2
A 3 000; G 20; D 2
G 100; R 150; D 2
R 150; S 50; D 2
A 3 000; R 150; D 2
A 3 000; G 100; D 2
R 150; D 2
A 2 000; S 50; D 2
G 100; R 150; S 50; D 2
G 50; R 150; D 2
A 2000; G 200; S 100
A 2 000; G 150; D 3
G 50; S 50; Db 180
A 2000; S 50
A 2000; D 2
A 1500; 2 D
A 1500; D 1
A 2 000; G 100; P 240; D 1
A 1 500; R 150; D 3
R 150; P 240; D 3
R 150; S 50; D 2
G 30; S 50; D 2
R 100; 0 2






























Medications: A = alpha methyldopa dose in mg/day; P = propranolol in mg/day; G = guanethidine dose in mg/day; S = spironolactone in
mg/day; R = rauwolfia serpentina in mg/day; D = thiazide diuretic in tablets/day; Db = debrisoquine in mg/day_
inadequately controlled on large doses of several other
antihypertensive drugs, or reasonable control was obtained
with existing regimens but at the price of significant side-
effects.
The details of the patients, including their blood
pressures on first referral to the clinic, fundoscopic gra-
ding and blood pressures on existing antihypertensive
regimens at the time of admission into the c10nidine trial,
are indicated in Table I. The daily amounts of their
antihypertensive drugs are shown as well as the duration
of treatment on these drugs.
Informed consent was obtained from all patients. Since
patients with severe hypertension were selected, a protocol
providing for addition of either c10nidine or its matching
placebo was chosen, rather than a protocol whereby
current medicines were discontinued and replaced by
either active drug or placebo. Clonidine or placebo was
added at random, 1 tablet t.i.d. for a period of one
month, after which alternative coded tablets were subs-
tituted without the knowledge of the patient. Each patient,
therefore, received both c10nidine and placebo for one
month with a random allocation of either c10nidine or
placebo during the first of the two months. At the start
and end of the two-month period electrolyte values,
urea, creatinine and an SMA-12 channel screen including
serum proteins, uric acid and serum epzymes were
obtained.
At each visit, sitting and standing blood pressures were
recorded without any alteration in the Clinic routine for
the patient. The patients were asked whether they noticed
anything different while on the tablets. Leading questions
about side-effects were avoided.
The results were analysed by an analysis of variance,
using an Olivetti Programma P203 computer. A P value
of less than 0,05 was regarded as indicating sirnificant
changes.
Single-Blind Group
In this group were included patients with severe hyPer-
tension and concomitant renal failure who were confined
to bed because of the severity of their hypertension.
Selection of patients was on referral to the Hypertension
Service. Only in one patient was a double-blind addition
trial attempted, but this was ceased when a hypertensive
response was noted on switching from c10nidine to placebo
tablets. (This is shown in Fig. 1.)
In a second group of patients with significant renal
failure, c10nidine was added to their existing antihyper-
tensive regimen and the patients followed up as outpatients
in the Hypertension Clinic. They were seen every month
or more frequently, and had frequent estimations of blood
chemistry determinations. The details of these patients are
shown in Table n.
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Fig. 1. The supine blood pressure responses of a patient during addition of c10nidine hydrochloride, 150 /lg ever)' 8 hours
at first, and then 150 /lg every 6 hours. The substitution of c10nidine with its placebo is followed by a rapid, severe rise
in blood pressure. This was the only patient in this group who received placebo therapy.
I
<
TABLE 11. PATIENTS WITH MILD RENAL FAILURE WHO ENTERED THE DOUBLE-BLIND TRIAL
On entry into trial On completion of trial
Urea Creat. Serum Urea Creat. Serum
(mg/l00 (mg/l00 Na+ Serum K BP (mg/l00 (mg/l00 Na- Serum K BP
ml) ml) (mEq/L) (mEq/L) (mmHg) ml) ml) (mEq/L) (mEq/L) (mmHg) Diagnosis
52 1,4 141 3,6 230/135 50 1,2 135 4,6 200/110 Benign
nephrosclerosis
91 3,4 139 4,5 200/120 78 3,0 141 4,2 160/90 Malignant
hypertension
72 2,7 140 5,1 160/100 110 5,8 140 3,9 150/90 Chronic
pyelonephritis
41 2,0 142 3,1 170/110 47 1,1 140 3,5 160/90 Benign
nephrosclerosis
70 2,8 138 4,7 230/150 64 1,7 137 2,7 160/115 Malignant
hypertension
66 2,4 143 4,8 160/110 37 1,1 142 4,2 140/100 Malignant
hypertension
96 3,0 140 4,5 210/110 98 2,2 142 5,3 150/90 Chronic
glomerulonephritis
to
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RESULTS
Ambulant Outpatients; Double-Blind Crossover
Group
postural effect in itself. A striking observation was the
slowing of the pulse rate which occurred in those patients
with the most marked reduction in blood pressures.
The incidence of side-effects was high. Four patients
withdrew because of intolerable sedation. Forty-two per
cent of the patients who completed the trial had bother-
some sedation, while 66% complained of a dry mouth.
Most patients felt these side-effects improved as the month
of treatment passed. In those patients who entered the
trial with normal haematological values and normal serum
chemistry, no changes in these measurements were seen.
The serum biochemical changes in those patients who
entered the trial with abnormal renal function, are shown
in Table H. Renal function remained unaltered in one
patient, deteriorated in one patient, and improved in 5
patients over the period of one month by the criteria of
serum urea and creatinine values. The patient who deterior-
ated died 8 months later from intractable renal failure.
Single-Blind Group with Severe Hypertension
Eleven patients were selected for this study. The details
of these patients are given in Table HI. Seven of these
patients had malignant hypertension at the time of entry
or immediately before referral; one had severe hyper-
tensive disease with renal impairment but only grade H
retinopathy. One patient had chronic glomerulonephritis
diagnosed on the basis of bilaterally small kidneys with
normal calyceal patterns on IVP, while two patients had
chronic pyelonephritis diagnosed on the basis of irregular-
ly-contracted kidneys. The duration of treatment with
c1onidine, the daily dose of this and the other drugs
received by these patients, are included in this Table.
The average blood pressure readings during the last 3
visits to the Clinic are indicated, and the serum urea and
creatinine values at their last Clinic visit at the time of
final assessment, June-August 1973, are included.
There was a satisfactory outcome in 10 of these patients
with a mean follow-up period of 14,6 months, although
normal blood pressures were obtained in only 3 patients.
Renal function clearly deteriorated in 2 patients, was
clearly improved in 5 patients, and remained unchanged
in 4. Particularly notable was the return to normal function
in 2 patients who had unequivocal malignant hypertension
at the time of their entry into the trial. No patient
was managed on clonidine alone.
Five of these patients were studied initially while con-
fined to bed. The blood pressure responses of 2 are
shown in Figs ! and 3 respectively. In Fig. I the supine
blood pressures of one of the patients are shown. This
was the only patient in whom a double-blind study was
attempted. The rapid rebound of blood pressure on
replacement of active principle with placebo is demon-
strated. This phenomenon was considered potentially
dangerous in these patients, and thereafter the study was
conducted in single-blind fashion. The response of another
patient is indicated in Fig. 3. All blood pressures were
recorded in the supine posture. This patient has returned
to. normal function, and is at work with a normal blood
pressure on maintenance therapy with 225 p..g clonidine,
















Fig. 2. ~1ean blood pressure responses in sitting and
standing positions before entering into the triaJ, at the end
of one month of placebo addition to their therapy, and
after one month of clonidine addition.
Eleven patients had active principle added to their
medications during the first month. while 14 patients
received placebo first, followed by active principle during
the second month. Four of the 25 patients who were
admitted to the trial developed intolerable sedation on
active principle and withdrew from the trial. The blood
pressure responses of the remaining 21 patients are shown
in Fig. 2. A lowering of diastolic pressure by more than
20 mmHg was obtained in 18 patients, while diastolic
pressures below 100 mmHg were obtained in 13 patients.
The mean sitting blood pressures (± I SEM) on entry
into the trial were 208 ± 6,0 mlT'.Hg, with the mean upright
122±3,7
blood pressure 198 ±7,2 mmHg. There was no change in
121 ±3,2
either the sitting or standing diastolic pressures during
the placebo period. A significant reduction in sitting and
standing systolic pressures occurred to 196 ± 6,4 mmHg
and 187 ±5,2 respectively (P<0,5 in both instances). This
finding emphasises the necessity for double-blind studies
in hypertension.
After addition of 450 p..g active principle daily for
a month, the sitting blood pressures were 162±5,0 mmHg;
98±2,5
upright blood pressures 153 ±4,3 mmHg. Statistical analy-
9H2,7
sis revealed a significant reduction at the I o~ level in
each instance. There was no significant increase in postural
response caused by the drug. Clonidine therefore caused
a highly significant reduction in both systolic and diastolic
pressures in both sitting and standing postures but had no
-
2 Maart 1974 S.-A. MEDIESE TYDSKRIF 395
so, c ... 1,
I TAl 12""1,.










































Fig. 3. The blood pressure response of a patient with
malignant hypertension before and after addition of 150 /lg





Several of these patients complained of sedation. It was
felt that this was in fact an advantage in those patients
confined to bed.
Clonidine hydrochloride is an imidazole derivative with
an apparently unique mode of action. This drug, active
in rg quantities, acts in 2 ways:'
Central action: It is a central sedative which acts at the
vasomotor centre to modify afferent impulses causing a
reduced sympathetic and increased parasympathetic out-
flow. The sympathetic reflexes are maintained intact.
The reduction in blood pressure is a function of the
decrease both in pulse rate and in peripheral resistance.'
Peripheral action: At a vascular smooth muscle leveI:
this takes a longer time to develop. The action of this
drug in alieviating the frequency and severity of migraine
attacks in some patients is collatefal evidence of this.'
It has also been postulated that the drug may act as
a ,B-adrenergic blocking agent, since the heart is slowed
and the actions of clonidine are antagonised by a-adre-
nergic blocking drugs.' Animal studies have failed to
show an action in reducing myocardial con tractility.'
In patients advantages of clonidine hydrochloride are
the absence of a postural effect and its potent action in
the supine state. The use of large doses of sympathetic
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postural hypotension can. therefore. be avoided. The
potent action in the supine posture coupled with the lack
of an effect on sympathetic reflexe, makes the drug a
suitable agent for use in patients due for anaesthe ia.
The relatively short action permits rapid adjustment of
dosage, but necessitates a 3- or 4-times-a-day dosage
schedule.
In patients with severe hypertension, the extent and
progression of the concomitant renal failure often deter-
mines the prognosis of the patient. Conversely, in this group
{)f patients, the control of the blood pressure is the most
important factor in determining the outcome of the renal
failure. The use of drugs that diminish renal blood flow.
e.g. guanethidine, bethanidine, reserpine and the diuretics.
hould therefore be avoided. The only drugs known not
to reduce renal blood flow are hydrallazine, alphamethyl-
dopa and the ~-adrenergic blocking agents. Onesti et at.'
have demonstrated that clonidine hydrochloride, while
antihypertensive, does not cause a diminution of renal
blood flow. The present tudy confirm these observations
at a clinical level. Although not controlled for the reasons
discussed, the outcome of the majority of patients over
a mean follow-up period of 14 months. was very gratifying
in a disea e with a natural history of less than 6 months,
if left untreated. These results are supported by the
observations published recently by Raftos er al.' who
reported on 39 patients treated for more than 2 years
with good results in 60 uu. The value of and freedom from
side-effects on long-term treatment with clonidine alone.
or in combination with a diuretic. have recently also been
recorded by Mroczek el al."
Current practice in the Hypertension Clinic at Groote
Schuur Hospital is therefore to place all patients with
hypertension and renal failure on a combination of
clonidine, hydrallazine and a ~-blocking drug or alpha-
methyldopa with minimal use of diuretics.
Clonidine has been shown to cause a mild degree of
"Sodium retention" and therefore is best used with a
<diuretic. Since the drug does not cause reduction in
'splanchnic blood flow it is recommended by some authors
Jor use in hypertension during pregnancy." It appears to
'have no teratogenic effect and some authors feel that it
is the drug of choice in the management of hypertensive
crises in pregnancy."
The high incidence of bothersome side-eff~cts (sedation
'and dry mouth) was offset by the impressive absence of
serious side-effects, even with administration of doses
up to 2400 fJ-g daily for over a year. The recent publication
by Mroczek eT aC· reported similar findings. The drug
appears, therefore. to be relatively safe and has a low
incidence of interaction with other drugs. The diminution
of the antihypertensive action of c10nidine by a tricyclic
.antidepressant desipramine, has recently been documented."
Current practice in our Clinic is to commence with a
smaller dose, 75 fJ-g l.i.d., with increment of 75 fJ-g per day
only. This appears to decrease the severity of the side-effects
until patients adapt to and tolerate the sedation and dry
mouth.
The hypertensive response on withdrawal of c10nidine
reported in this study, has been documented by others."·16
It appears to occur mostly in severely hypertensive patients.
These patients are often on other drugs as well, and these
may serve to diminish this potentially serious side-effect
of clonidine. Clinically it appears of little importance,
since with widespread use of the drug no cerebrovascular
or cardiac episodes attributable to this hypertensive over-
shoot have been reported. Caution has to be exercised in
patients undergoing general anaesthesia. since such a
hypertensive episode may complicate the anaesthetic. It is
therefore recommended that clonidine be continued un-
interrupted thoroughout the pre-, intra- and postopera-
tive period, resorting to parenterally administered clonidine
if oral administration is not feasible. The hypertensive
overshoot itself usually responds readily to parenteral
clonidine or ~-adrenergic blocking drugs.
In conclusion, it was found that clonidine hydro-
chloride caused a significant antihypertensive effect on
being added to the various antihypertensive regimens of
these patients with problematical hypertension. Those with
renal failure were satisfactorily managed by the addition
of the drug. while its inclusion in regimens for malignant
hypertension assisted improvement in the majority of
cases. Its high rate of bothersome side-effects is compen-
sated for by the relative safety on long-term administration.
I wish to thank Dr M. H. DUrr of Boehringer Ingelbeim for
the supply of coded tablets.
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